About CMS
Company Overview
CMS is a securities company registered in Hong Kong, China, and was founded on 22 September 2017. The firm is headquartered at 48/F., One Exchange Square, Central, Hong Kong, a prominent financial district location.
According to regulatory records, CMS holds a Derivatives Trading License (AGN) from the Securities and Futures Commission (SFC) of Hong Kong, with a status of 'Regulated.' This license authorises the firm to engage in dealing in futures contracts, though the scope of its regulated activities may extend to other products.
Regulation and Licensing
The sole regulator on file for CMS is the SFC, which is a well-respected financial regulator in Asia. The SFC license number is AGN, and the firm is classified as a 'Regulated' entity under Hong Kong law.
Our cross-check against the SFC public register confirms the licence is active. However, the specific licence type (Type 2 – Dealing in Futures Contracts) suggests CMS is authorised to offer futures trading, which commonly includes forex futures, commodity futures, and index futures.
Products and Services
CMS supports a broad range of trading instruments, including Futures, Commodities, Funds, Stocks, Bonds, Options, ETFs, and Indices. This multi-asset offering positions the firm as a versatile platform for diversified trading strategies.
The company claims to provide 6 trading platforms and 3 account types, though specific platform names and account features are not detailed in regulatory records. The absence of independent user reviews means traders must exercise caution and verify available details directly with the broker.
FXCanary Scam Risk Assessment
FXCanary has assigned CMS a Scam Risk Score of 38 out of 100, categorised as 'Guarded.' This score reflects the presence of a credible SFC regulation and a Hong Kong base, but also accounts for the lack of independent user feedback and limited publicly available information about trading conditions.
Traders are advised to conduct thorough due diligence, including verifying the broker's claims against the SFC register and testing any demo accounts before committing funds.
Overview compiled by FXCanary from regulatory records and public data. full CMS review